(S)-4-phenyloxazolidine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-4-phenyloxazolidine
• 英文别名: (4S)-4-phenyl-1,3-oxazolidine
• 化学式: C₉H₁₁NO
• 分子量: 149.192
• InChiKey: SBJSTQONOOUZKC-SECBINFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (S)-4-phenyloxazolidine 在 盐酸 、 1-羟基苯并三唑 、 sodium hydroxide 作用下， 以 甲醇 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-[(2S,3S)-3-hydroxy-4-oxo-1-phenyl-4-[3-(2H-tetrazol-5-yl)anilino]butan-2-yl]-4-methoxy-6-[(4S)-4-phenyl-1,3-oxazolidine-3-carbonyl]pyridine-2-carboxamide
  参考文献：
  名称：

  Structure–activity relationship study of BACE1 inhibitors possessing a chelidonic or 2,6-pyridinedicarboxylic scaffold at the P2 position

  摘要：

  We have previously reported potent substrate-based pentapeptidic BACE1 inhibitors possessing a hydroxymethylcarbonyl isostere as a substrate transition-state mimic. While these inhibitors exhibited potent activities in enzymatic and cellular assays (KMI-429 in particular inhibited A beta production in vivo), these inhibitors contained some natural amino acids that seemed to be required to improve enzymatic stability in vivo and permeability across the blood-brain barrier, so as to be practical drug. Recently, we synthesized non-peptidic and small-sized BACE1 inhibitors possessing a heterocyclic scaffold at the P-2 position. Herein we report the SAR study of BACE1 inhibitors possessing this heterocyclic scaffold, a chelidonic or 2,6-pyridinedicarboxylic moiety. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.12.007
• 作为产物：
  描述：

  聚合甲醛 、 L-苯甘氨醇 在 对甲苯磺酸 作用下， 以 苯 为溶剂， 反应 4.0h， 生成 (S)-4-phenyloxazolidine
  参考文献：
  名称：

  新型简单手性膦恶唑烷配体：在钯催化的不对称烯丙基烷基化反应中的简单合成及应用

  摘要：

  新型手性膦-恶唑烷已从光学活性氨基醇开始，通过简单的一锅法很容易合成。它们在 Pd 催化的 1,3-二苯基-2-丙烯基乙酸酯与丙二酸二甲酯的不对称烯丙基烷基化反应中进行了筛选。反应顺利进行，产率良好至极好，并获得了极好的立体选择性（高达 97%）。

  DOI：

  10.1055/s-2005-868475

文献信息

• Aminoheteroaryl benzamides as kinase inhibitors
  申请人：Bagdanoff Jeffrey T.

  公开号：US09242996B2

  公开（公告）日：2016-01-26

  The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.

  本发明提供了化合物的化合物（I）或其盐； 以及这些化合物的治疗用途。本发明还提供了包含这些化合物的药物组合物，以及包含这些化合物与治疗辅助剂的组合物。
• New Simple Chiral Phosphine Oxazolidine Ligands: Easy Synthesis and ­Application in the Palladium-Catalyzed Asymmetric Allylic Alkylation
  作者：Antonio Braga、Jasquer Sehnem、Diogo Lüdtke、Gilson Zeni、Claudio Silveira、Miriam Marchi

  DOI：10.1055/s-2005-868475

  日期：——

  types of chiral phosphine-oxazolidines have been easily synthesized in a straightforward one-pot process starting from optically active aminoalcohols. They were screened in the Pd-catalyzed asymmetric allylic alkylations of 1,3-diphenyl-2-propenyl acetate with dimethylmalonate. The reaction proceeds smoothly in good to excellent yields and excellent stereoselectivity was obtained (up to 97%).

  新型手性膦-恶唑烷已从光学活性氨基醇开始，通过简单的一锅法很容易合成。它们在 Pd 催化的 1,3-二苯基-2-丙烯基乙酸酯与丙二酸二甲酯的不对称烯丙基烷基化反应中进行了筛选。反应顺利进行，产率良好至极好，并获得了极好的立体选择性（高达 97%）。
• [EN] NECROSIS INHIBITORS<br/>[FR] INHIBITEURS DE NÉCROSE
  申请人：NAT INST OF BIOLOG SCIENCES BEIJING

  公开号：WO2016101887A1

  公开（公告）日：2016-06-30

  The invention provides amides that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

  该发明提供了抑制细胞坏死和/或人类受体相互作用蛋白1激酶（RIP1）的酰胺，包括相应的磺酰胺，以及其药用盐、氢化物和立体异构体。这些化合物用于制备药物组合物，并用于制备方法，包括用有效量的化合物或组合物治疗需要的人，并检测人的健康或状况的改善。
• NOVEL COMPOUND HAVING SECRETASE INHIBITORY ACTIVITY
  申请人：Kiso, Yoshiaki

  公开号：EP2168947A1

  公开（公告）日：2010-03-31

  A novel compound represented by the formula (1) below which has β-secretase inhibitory activity, its pharmaceutically acceptable salt or a prodrug thereof. wherein Ar is a substituted or unsubstituted 5 to 6 membered mono cyclic aromatic group; R1, R2 and R3 are hydrogen atom, substituted or unsubstituted alkyl group or the like, or R2 and R3 may be taken together with the adjacent nitrogen atom and carbon atom respectively to form a 3 to 6 membered ring; R4 is C1-6 alkyl group, C1-6 alkyl group substituted by phenyl, phenylthio, or a hetero ring, or the like; A is represented by the formula below: wherein X and Y are oxygen atom, NH or sulfur atom, Z is hydrogen atom, hydroxy group which may be substituted, amino group, thiol group, or the like; and B is hydroxy group, substituted or unsubstituted amino group, substituted or unsubstituted aliphatic or aromatic amino group, or the like.

  下面的公式（1）表示的一种新化合物具有β-分泌酶抑制活性，其药用可接受的盐或其前药。其中Ar是取代或未取代的5至6个成员单环芳香基团；R1、R2和R3是氢原子，取代或未取代的烷基或类似物，或R2和R3可以分别与相邻的氮原子和碳原子结合形成3至6个成员环；R4是C1-6烷基，C1-6烷基被苯基，苯硫基或杂环取代，或类似物取代；A由以下公式表示：其中X和Y是氧原子，NH或硫原子，Z是氢原子，可被取代的羟基，氨基，硫醇基等；B是羟基，取代或未取代的氨基，取代或未取代的脂肪或芳香氨基，或类似物。
• [EN] A PROCESS FOR THE PREPARATION OF NUCLEOSIDE PHOSPHORAMIDATE<br/>[FR] PROCÉDÉ DE PRÉPARATION DE PHOSPHORAMIDATE DE NUCLÉOSIDE
  申请人：LUPIN LTD

  公开号：WO2016016865A1

  公开（公告）日：2016-02-04

  The present invention pertains to process for preparing nucleoside phosphoramidate and its intermediate. The present invention provides novel intermediate, its process for preparation and its use for the preparation of Sofosbuvir.

  本发明涉及制备核苷酸磷酰胺及其中间体的方法。本发明提供了新型中间体，其制备方法以及其用于制备索非布韦的用途。